What happened with CRON today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Cronos Group Inc. supplies cannabis for adult use and medical patients, with Canada generating most of its revenue and cannabis flower accounting for most product sales. In Canada’s adult-use market, it sells Spinach and Lord Jones products mainly to provincial and territorial cannabis authorities, which supply the retail market. It also sells directly to private retailers in Saskatchewan. Ontario Cannabis Retail Corporation and Alberta Gaming, Liquor and Cannabis Commission together account for a substantial share of revenue.
Outside Canada, the business chiefly serves medical markets through pharmacies and distributors, with Israel its largest foreign market. PEACE NATURALS and LIT are among its medical brands; Cansativa distributes its products in Germany. Cronos GrowCo supplies most of the company’s cannabis and also sells wholesale cannabis to other buyers.
Sales depend on consumer demand and continued access to regulated distribution channels. Canadian authorities do not commit to minimum purchases and can change prices or stop buying. Production requires cannabis licenses, and Canadian exports need shipment-specific permits limited to medical or scientific purposes. Overseas sales also depend on partners meeting local import and regulatory requirements.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Organigram Global Inc. competes for Canadian adult-use cannabis buyers with flower, pre-rolls, gummies and hash that rival Cronos’s Spinach and Lord Jones products. Its brand and product-format launches are worth watching for competition across consumer needs and price tiers.
Canopy Growth Corporation competes with Cronos for Canadian adult-use cannabis buyers and medical patients in Germany and Australia. Its medical sales in those two countries offer a closer comparison for Cronos’s overseas business than its plans to enter the UK, where Cronos already sells products.
Aurora Cannabis Inc. competes with Cronos in medical cannabis flower and extracts in Canada and overseas, but sells directly to registered Canadian patients while Cronos uses third-party distributors. Watch Aurora’s medical business with that distinction in mind: the Canadian reimbursement change effective April 1, 2026 is expected to reduce its reimbursement by about 30%, rather than signal a matching decline for Cronos.
Tilray Brands, Inc. competes with Cronos for Canadian adult-use cannabis buyers and international medical cannabis patients. Its beverage and other businesses make overall results a less direct comparison, so focus on its cannabis business.
IM Cannabis Corp. competes with Cronos for medical patients in Israel and Germany, importing and selling branded cannabis through pharmacies and distribution channels. Its shift of resources toward Germany is worth watching alongside Cronos’s PEACE NATURALS and LIT sales there.
Village Farms International, Inc. competes with Cronos in Canadian cannabis through Pure Sunfarms and Rose LifeScience. Watch those Canadian cannabis businesses rather than group-wide results, which also include produce, overseas cannabis and renewable natural gas royalties.
Altria Group, Inc. is a major influence on Cronos’s capital and strategic decisions: at December 31, 2025 it owned 41%, with rights to nominate four of seven directors and approve specified transactions. Altria sells tobacco and nicotine products mainly to US wholesalers and large retailers, so its Cronos-related investment and governance news matters more here than its tobacco sales.
High Tide Inc.’s Canadian stores sell cannabis to consumers in the same adult-use market that Cronos supplies with branded products; Cronos also lent it money that can be converted into shares by agreement and holds a right to buy shares, a warrant. Canadian store sales are the clearest demand read-through: they supplied about 96% of High Tide’s external-customer revenue in the fiscal year ended October 31, 2025.
Sundial Growers Inc. (SNDL) grows and sells cannabis for Canadian adult-use and medical customers, competing in markets served by Cronos, and also sells adult-use products through Value Buds and Spiritleaf stores. Focus on its cannabis operations and retail sales rather than total revenue: its separate liquor retail business generated CAD 539.6 million in 2025.
Sundial Growers Inc. earningsSNDL
SNDL's report will show how cannabis sales and retail demand are faring in Canada, where its cannabis business competes with Cronos Group.
Focus on SNDL's cannabis operations and cannabis retail sales, not its liquor retail revenue. If both grow, Canadian cannabis demand and retail channels look more supportive for Cronos Group too. If they weaken, the market's sales or retail demand is under pressure, but that alone does not show that Cronos Group's own sales fell.
Cronos Group Inc. earningsThis company
Cronos Group's report will show whether it can sustain gross profit as Canadian sales improve, rather than relying mainly on growth in Israel and other international markets.
Compare sales in Canada with sales in Israel and other countries, then check whether gross margin holds. Stronger Canadian sales alongside steady international sales and a stable or rising margin would show that growth is broadening without weakening profitability. Persistently weak Canadian sales or a falling margin would show that growth remains concentrated overseas or is bringing less gross profit.
IM Cannabis Corp. earningsIMCC
IM Cannabis's report will show how medical cannabis demand is changing in Israel and Germany, markets that overlap with Cronos Group's international business.
Look at IM Cannabis's medical sales in Israel and Germany, including whether Germany is growing; its sales channels differ from Cronos Group's, so the two companies are not a like-for-like sales comparison. Strength in both markets would point to supported medical demand where they overlap. Weak sales, or German growth alongside a decline in Israel, would show that demand is uneven and Cronos Group's exposure cannot be treated as one market.
